Next Article in Journal
Carbon Microsphere-Supported Metallic Nickel Nanoparticles as Novel Heterogeneous Catalysts and Their Application for the Reduction of Nitrophenol
Next Article in Special Issue
Luminescent Complexes of Europium (III) with 2-(Phenylethynyl)-1,10-phenanthroline: The Role of the Counterions
Previous Article in Journal
Design, Synthesis, and Biochemical Evaluation of New Triazole Derivatives as Aurora-A Kinase Inhibitors
Previous Article in Special Issue
Crystallographic and Spectroscopic Investigations on Oxidative Coordination in the Heteroleptic Mononuclear Complex of Cerium and Benzoxazine Dimer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 18
10.3390/molecules26185679
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

by
Yongjie Chen
1,*,
Lijuan Bai
1,
Pu Zhang
1,
Hua Zhao
1 and
Qianxiong Zhou
2,*
1
Research Center for Pharmacodynamic Evaluation Engineering Technology of Chongqing, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
2
Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China
*
Authors to whom correspondence should be addressed.
Molecules 2021, 26(18), 5679; https://doi.org/10.3390/molecules26185679
Submission received: 18 August 2021 / Revised: 12 September 2021 / Accepted: 13 September 2021 / Published: 18 September 2021
(This article belongs to the Special Issue Metal-Organic Complexes: Applications in Chemistry and Materials Science)
Browse Figures
Versions Notes

Abstract

:
Photoactivated chemotherapy (PACT) is a novel cancer treatment method that has drawn increasing attention due to its high selectivity and low side effects by spatio-temporal control of irradiation. Compared with photodynamic therapy (PDT), oxygen-independent PACT is more suitable for treating hypoxic tumors. By finely tuning ligand structures and coordination configurations, many Ru(II) complexes can undergo photoinduced ligand dissociation, and the resulting Ru(II) aqua species and/or free ligands may have anticancer activity, showing their potential as PACT agents. In this mini-review, we summarized the progress in Ru(II)-based PACT agents, as well as challenges that researchers in this field still face.

Graphical Abstract

1. Introduction

The research of new chemotherapeutic drugs for cancer treatment has been the focus in medicine and related fields for many years. Among them, the development of transition-metal-based agents has always been one of the hotspots [1,2,3,4,5,6,7], which obviously benefits from the long-term and wide clinical application of cisplatin [cis-Pt (NH3)2Cl2]. The unexpected discovery by Rosenberg and his co-workers revealed the antitumor activity of cisplatin in the 1960s [8,9]; subsequently, cisplatin and its analogs (Figure 1) have been successfully used in the clinical treatment of many cancers [10]. Although cisplatin and its derivatives are efficacious against the vast majority of cancers, their selectivity to tumor tissues and normal tissues is poor [11]. This leads to the production of non-cancer cell toxicity; thereby, severe adverse effects are caused, including hair loss, peripheral neuropathy, and myelotoxicity in patients [12,13,14].
Many strategies have been used for solving the above problems, for example, using targeting drug delivery systems and developing reduction responsive Pt(IV) prodrugs [15,16]. In addition, many photoactivated Pt(IV) agents have been reported, which are nontoxic in the dark but can release cytotoxic Pt(II) species upon light irradiation [17,18]. These kinds of prodrugs are commonly known as photoactivated chemotherapy (PACT) agents, which can trigger and limit the drug activity within the tumor tissues by spatio-temporal control of irradiation, thus achieving fewer side effects [19,20,21]. Compared with traditional photodynamic therapy (PDT) [22,23], another phototherapy that is generally oxygen-dependent, PACT offers an oxygen-independent mechanism, and is therefore more suitable for hypoxic tumors, where the concentration of oxygen is remarkably low [24,25].
Inspired by the success of Pt complexes as antitumor drugs, other transition metal complexes, especially Ruthenium (Ru) complexes, have drawn great attention owing to their potential anticancer properties and selective cytotoxic activity [26]. Investigating new Ru-based complexes as anticancer drugs is an important trend in modern medicinal inorganic chemistry [27,28,29,30]. Up till now, several Ru(III) complexes as chemotherapeutic agents have already entered clinical trials, such as NAMI-A, KP1019, and KP1339 (Figure 2) [31,32,33,34,35]. As the first approved Ru complex to reach clinical investigations, NAMI-A showed success in phase I clinical studies but showed only limited efficacy in the phase II stage, which resulted in the failure of the clinical investigations [27,36]. Afterward, another Ru therapeutic KP1019 showed solubility limited in phase I, but in its place, a more soluble sodium salt, KP1339, is currently undergoing clinical trials [27]. Different from focusing on the chemotherapeutic activity of Ru(III) complexes, more attentions has been paid to the photoactivation of Ru(II) complexes. TLD1433, the first Ru(II)-based photosensitizer for PDT, has already entered human clinical trials [37]. Moreover, studies have also indicated that Ru(II) complexes may possess potential as PACT agents [38,39,40,41]. Through proper structure design, they can undergo photoinduced ligand dissociation; then, the resulting Ru(II) aqua species can covalently bind to DNA in a manner similar to cisplatin. Compared with Pt(IV) complexes, Ru(II)-based PACT agents have some promising advantages. They possess diverse and easy-modified structures, rich photophysical and photochemical properties, and furthermore, the octahedral structures different from that of cisplatin may endow them with good activity against cisplatin-resistant cancer cells [42,43,44].
The lowest energy absorption band of Ru(II) complexes usually comes from 1MLCT (Metal-to-Ligand Charge Transfer) transitions. When irradiated by appropriate light, Ru(II) complexes first achieve the 1MLCT state and then reach the 3MLCT state through ultra-fast intersystem crossing (Figure 3) [19]. The 3MLCT state of Ru(II) complexes can return to the ground state through non-radiative inactivation or luminescence pathways [45,46] or can interact with other molecules such as O2 to generate singlet oxygen (1O2), showing potential as photodynamic agents [47,48,49]. This paper focuses on another photochemical process: the 3MLCT excited state of Ru(II) complexes may populate the 3MC state (metal-centered state or ligand-field state) by thermal activation. The 3MC state has M-L (σ*) character, which may lead to ligand dissociation and generate Ru(II) aqua species with DNA-binding ability, showing potential in photoactivated chemotherapy. This mini-review aims to present the latest progress in photoinduced ligand dissociation related Ru(II)-based PACT agents for cancer treatment. By reading this article, we hope to not only let our peers know about the all-around development of Ru(II)-based PACT drugs but also inspire more researchers to enter this interesting field.

2. Ligand Photodissociation of Ru(II) Polypyridyl Complexes

Theoretically, the activity of Ru(II)-based PACT agents is closely related to their photoinduced ligand dissociation efficiency. Therefore, the research on ligand dissociation efficiency is the focus of developing potential Ru(II)-based PACT drugs.

2.1. Photodissociation of Monodentate Ligands

The development of photoinduced ligand dissociation and consequently DNA binding of Ru(II) complexes began with a report by Turro and colleagues in 2004 [50]. The photolysis of cis-[Ru(bpy)2(NH3)2]2+ (bpy = 2,2′-bipyridine, complex 1 in Figure 4) in water was investigated. Irradiation of 1 resulted in the sequential loss of the NH3 ligands and the formation of the corresponding bis-aqua complex cis-[Ru(bpy)2(H2O)2]2+. The photodissociation of ligands was dependent on the excitation wavelength. Under 350 nm and 400 nm light, the ligand exchange quantum yields were 0.024 and 0.018, respectively. Upon irradiation, 1 can form covalent binding with 9-methylguanine, 9-ethylguanine single-stranded and double-stranded DNA.
The photodissociation efficiency of the monodentate ligand is closely related to its coordination ability. Compared with 1, the photoinduced ligand exchange quantum yield for cis-[Ru(bpy)2(py)2]2+(py = pyridine, 2) between pyridine and Cl- was only 0.0059 [51], while the quantum yield of cis-[Ru(bpy)2(H2O)2]2+ formed by illumination of cis-[Ru(bpy)2(CH3CN)2]2+(3) in water was as high as 0.38 (350 nm) and 0.22 (450 nm) [52]. The photoinduced ligand exchange reaction of 1 and 3 in an aqueous solution was studied using the density functional theory (DFT) by Kayanuma and co-workers [53]. The 3MC structure was lower in energy than the 3MLCT structure for 3; in contrast, the 3MLCT structure was lower in energy than the 3MC structure for 1. Such a difference would correlate with the higher photoinduced ligand dissociation quantum yield of 3 compared to 1.
Glazer et al., reported three Ru(II) polypyridyl complexes 4–6 [54] with isomeric diazine ligands, and their photochemical properties were compared to 2. It was found that unlike 2, which photodissociated only one monodentate ligand in water, 4–6 released both monodentate ligands, with the quantum yields of the second phase varying from the ligand pKa and medium pH. These results suggest that the photochemistry of these complexes can be tuned by simple electronic effects.
The photodissociation efficiency of the monodentate ligand is also related to the distortion degree of octahedral Ru(II) complexes. Thus, the steric bulk is introduced to distort the octahedral field to lower the energy of the 3MC state and reduce the energy gap between the 3MC state and 3MLCT state, which will finally result in greater yields of ligand photodissociation. The photochemical behavior of a series of complexes [Ru(TPA)(CH3CN)2] (TPA = tris[(pyridin-2-yl)methyl]amine, 7–10) reflects the steric effect very well [55]. The quantum yield of photosubstitution in 7 was measured as 0.009 (400 nm) in water, while that of 8 was 0.011 under the same conditions. Due to the large steric crowding of 9 and 10, the CH3CN ligand can be released even in dark conditions. Lately, complex [Ru(1-isocyTPQA)(CH3CN)2]2+ (1-isocyTPQA = 1-(((2R,6S)-2,6-bis(pyridin-2-yl)piperidin-1-yl)-methyl)isoquinoline, 11) was designed and synthesized by Kodanko and co-workers, which exhibited unique photochemical properties distinct from 7–10 [56]. It was found that the greatly enhanced quantum efficiency (Φ400 = 0.033 in water) of photodissociation in 11 can be explained by a trans-type effect in the 3MLCT state. DFT calculations and ultrafast transient spectroscopy revealed that a highly mixed 3MLCT/3ππ* excited state instead of 3MC is the lowest-energy triplet state of 11. This research validated that orbital mixing and steric effects can have a strong influence on photoinduced ligand exchange.
The steric bulk effect is also found in complexes 12–14 [57]. The pyridine dissociation quantum yield upon 500 nm irradiation in CH3CN was 0.16 and 0.033 for 13 and 14, respectively. While under the same conditions, ligand exchange was not observed in 12, which lacks steric strain. The ligand photodissociation behavior of cis-[Ru(biq)(phen)(CH3CN)2]2+(biq = 2,2′-biquino-line, phen = 1,10-phenathroline, 15) is very unique [58]. Upon irradiation with low energy light (≥550 nm), only one CH3CN ligand can exchange with the solvent molecule, but both ligands exchanged with the solvent molecule upon irradiation with high energy light(≥420 nm). In contrast, two CH3CN ligands of 16 and 17 were able to exchange with solvent molecules under both light conditions. The theoretical calculations gave a certain explanation for these results. The photodissociation of the ligand of 15 may occur through a so-called “dissociative” mechanism, in which the ligand leaves first to produce five-coordination intermediates. DFT calculations showed that the coordination vacancy of the five-coordination intermediate with the lowest energy forms a trans configuration with phen, which means that the CH3CN ligand trans to phen leaves preferentially.
Recently, Glazer’s group investigated the interplay of steric and electronic features that impact the photodissociation efficiency of monodentate ligand for Ru(II) complexes [59]. The experimental results showed that rationally varying the ligand components and structures of the metal complex could result in a better photodissociation efficiency.
Additionally, to explore the role of modification on the retaining ligands in the anticancer activity of Ru(II) PACT agents, Zhou et at. reported complexes 18–21, which can photorelease one pyridine ligand and covalently bind to DNA [60]. The study found that compared with 18, the fluorinated complexes 19–21 exhibited enhanced phototoxicity, yet diminished dark cytotoxicity, more favorable for PACT applications. Lately, by introducing the strong electron-withdrawing –NO2 groups, two mitochondria-localized complexes 22–23 were designed and synthesized [61]. These two complexes can photo-catalyze NADH (β-nicotinamide adenine dinucleotide) depletion and photoinduce ligand dissociation to damage the mitochondrial DNA simultaneously, thus display good activity towards cisplatin-resistant cancer cells.

2.2. Photodissociation of Bidentate Ligands

Compared with monodentate ligands, the photodissociation of bidentate ligands is much more difficult due to the chelation effect. Although the two NH3 ligands of cis-[Ru(bpy)2(NH3)2]2+(1) can be readily photoreleased, the quantum yield of ethanediamine (en) ligand exchange with Cl− for [Ru(bpy)2(en)]2+ (24, Figure 5) is only 0.002 [62]. Similar to 24, the quantum yield of ligand exchange for 25 is only 0.003.
By taking some effective strategies, bidentate ligands can also serve as photolabile ones to expose two active sites at the same time. An effective strategy to improve the dissociation efficiency of bidentate ligands is to weaken the coordination ability of the coordination atoms. For example, compared with 24 and 25, the photodissociation quantum efficiency of weaker bis-thioether ligands in 26 and 27 increase significantly, which are 0.019 and 0.016, respectively [62]. These two complexes can effectively reduce the mobility of linearized pUC18 plasmid DNA in electrophoresis upon irradiation, indicating that they can covalently bind to DNA and show potential in PACT.
Another effective strategy to improve the dissociation efficiency of bidentate ligands is to utilize steric bulk. Glazer and co-workers designed two new complexes 28 and 29 [63]. Through the substitution of two methyl groups on the 6 and 6′ positions of bpy, and 2 and 9 positions of dpq (dpq = dipyrido [3,2-f:2′,3′-h]-quinoxaline), steric bulk was successfully introduced into 28 and 29. When the two complexes are illuminated, Me2bpy and Me2dpq can be effectively dissociated, and the resulting hydrate can covalently bind to plasmid DNA, reducing the DNA mobility on agarose gels electrophoresis. Interestingly, 29 can photocleave and photobind DNA at the same time, which indicates that photosensitization of singlet oxygen can compete with the ligand dissociation decay pathway. It was worth mentioning that the photo-cytotoxicity increased by 2 orders of magnitude for 28 and 29. According to the same idea, a series of Ru(II) complexes with steric bulk have been studied in depth [64,65,66,67,68].
Khnayzer et al., reported a sterically crowned complex 30, which can release either bpy or dmphen (2,9-dimethyl-1,10-phenanthroline) ligands upon visible light irradiation in water [65]. It is noteworthy that the phototoxicity of 30 towards the ML-2 Acute Myeloid Leukemia cell line appears to come from dmphen rather than the bis-aqua photoproduct [Ru(bpy)2(H2O)2]2+. In another study, by comparing the ligand toxicity, lipophilicity, and cellular uptake of complexes 28 and 31, Bonnet et al. found that the phototoxicity of 28 comes from the photoreleased dmbpy ligand, whereas the only phototoxicity species is the bis-aqua photoproduct in 31 [69]. A series of Ru polypyridyl complexes based on the nontoxic 3-(methylthio)propylamine ligand were reported. It was found that by fine-tuning the lipophilicity and steric strain, the Ru-based PACT prodrugs can be phototoxic [70].
2,2′-biquinoline ligand (biq) not only has steric bulk but also extends the absorption wavelength of the Ru(II) complexes due to its conjugated structure. In accordance with this expectation, the MLCT absorption maximums of complexes 32 and 33 were extended to 525 nm and 550 nm, respectively [66]. Complexes 32 and 33 could release the biq ligand, which resulted in the retarded electrophoresis rate of plasmid DNA and phototoxicity towards HL60 cells under red light irradiation. In addition, Glazer’s group used cross-linked polymeric assemblies to load the strained Ru(II) complexes for the treatment of cancer and found that using polymeric nanoassemblies is a promising method to improve the pharmacological properties of Ru(II) complexes [67].
The Ruthenium complex [Ru(bpy)2(dppz)]2+ (dppz = dipyridylphenazine) displays the property of “DNA light switch”; that is, the emission of [Ru(bpy)2(dppz)]2+ is quite low in aqueous solution, and can be switched on in the presence of DNA. The dppz ligand can intercalate into DNA base pairs; thus, the hydrogen bond between two N atoms in the phenazine ring and water molecule is inhibited [71]. Although the Me2dppz ligand can cause steric clashes, the ligand photodissociation efficiency of [Ru(bpy)2(Me2dppz)]2+ (34) is very low. Meanwhile, the photodissociation process of the Me2dppz ligand is activated after DNA insertion, resulting in covalent binding of the complex to DNA after ligand photodissociation [72]. Further studies revealed that the ligand photodissociation of 34 is through the so-called “associative” mechanism; that is, the complex first coordinates with the exchange ligand to form seven coordination intermediates and then loses the coordination hindrance ligand Me2dppz [73].
Recently, to expand the applications of sterically congested Ru(II) polypyridyl complexes in PACT, Glazer al et. investigated the photochemical and biological properties of a series of Ru(II) complexes with photolabile pyridyl-pyrazol(in)e ligands [74]. Due to the introduction of a carboxylic, complexes 35 and 36 exhibited the largest PI values of 146 and 59, respectively, by a remarkable reduction of dark cytotoxicity.

3. Extending the Photoactivation Wavelength

Similar to other phototherapies, the wavelength of photoactivation for PACT agents is important for clinical applications. The ideal phototherapy window is between 650 and 850 nm [75], while photoactivating most Ru(II) complexes mentioned above requires high-energy visible light (< 500 nm), which may be harmful to normal tissues [76] and has poor tissue penetration [77]. How to extend the photoactivation wavelength to the ideal phototherapy window has become one of the important problems to be solved.
As mentioned above, the large conjugated structure of the biq ligand obviously extends the photoactivation wavelengths of complexes 32 and 33. On the one hand, the large conjugate system reduces the π* orbital energy of the biq ligand, thus reducing the energy of 1MLCT [t2g(Ru) to π*(biq)]. On the other hand, it causes steric hindrance, which reduces the 3MC energy through the distortion of the coordination field, and consequently ensures that efficient ligand dissociation can still occur upon low photon energy excitation. Recently, a nitro-anthraquinone group was attached to a biq-ligand-based Ru(II) complex by Wang and colleagues, endowing the resultant complex 37 (Figure 6) with multiple anticancer mechanisms upon irradiation in the phototherapy window [78]. It was found that 37 can release a biq ligand upon 600 nm irradiation, along with generating O2•− and oxidizing NADH/NADPH (β-nicotinamide adenine dinucleotide phosphate).
When the ring-metalized-ligands (such as 2-phenylpyridine, phpy) coordinate with Ru, the strong electron-donating capacity of carbon anions can significantly increase the t2g orbital energy of Ru(II), thus greatly prolongs the MLCT absorption wavelength. Using this strategy, Turro’s group designed and synthesized the complex cis-[Ru(phpy)(phen)(CH3CN)2]+ (38) [79]. The MLCT absorption peak of Ru(II) to phen ligand was at 490 nm, and the tail band extended to the phototherapy window. The quantum efficiency of ligand exchange between CH3CN and Cl- was up to 0.25 upon 450 nm excitation. Different from the wavelength dependence of photoinduced ligand dissociation mentioned above, under 400 nm light irradiation, the ligand exchange efficiency of 38 decreased to 0.08. It is believed that the MLCT transition at 400 nm is mainly from Ru(II) to phpy ligand. Since the absorption band at 400 nm also contains too much of the ππ* transition component of the phpy ligand, the ligand photodissociation efficiency decreases instead of increasing. Turro’s group further designed and synthesized the complex [Ru(biq)2(phpy)]+ (39) by combining the phpy and biq ligands [45]. Cyclometallation results in a redshift of the MLCT absorption maximum of 39 by about 100 nm relative to that of 32 and 33. Although 39 exhibited a distorted octahedral geometry, photoinduced ligand exchange did not occur. DFT calculations indicated that the difference of reactivity in 39 was ascribed to increased energy of 3MC states resulting from the bonding of the strong σ-donor phpy ligand. Bonnet et al. investigated the cyclometalated Ru complex 40, which contained photolabile N,S bidentate ligand and found that 40 can be active under 521 nm irradiation in CH3CN, which makes it the first cyclometalated Ru complex capable of undergoing photosubstitution of a bidentate ligand [80].
Turro et al. introduced new ancillary ligand platforms that consist of anionic acetylacetonate-based ligand along with tridentate 2,6-di(quinolin-2-yl)pyridine (dqpy) ligand into complex 41 [81]. Acetylacetonate ligands are strong π-donor ligands that used to destabilize the HOMO (highest occupied molecular orbital), whereas the dqpy ligand with its extended conjugation lowers the LUMO (lowest unoccupied molecular orbital) energy; both effects make the ligand substitution of 41 accessible with near-infrared (NIR) light (≥ 715 nm).
The MLCT absorption band of binuclear or polynuclear Ru(II) complexes constructed with bridged ligands tends to be significantly redshifted compared with that of corresponding mononuclear complexes [82,83,84]. As a result, the bridging concept was utilized to design the first dinuclear Ru(II) complex (42) capable of undergoing ligand dissociation at both metal centers upon ≥ 610 nm irradiation in H2O [85]. To further explore the effect of the bridging ligand on Ru(II)-based PACT agents, Dunbar et al. used quinoxaline-functionalized bridging ligand platforms to prepare corresponding binuclear complexes [86]. These complexes were capable of absorbing green light with tails extending beyond 650 nm, which is a promising feature for applications in PACT.
In recent years, upconversion nanoparticles (UCNPs), which produce high-energy light under NIR excitation, were successfully used to extend the photoactivation wavelength of Ru-based PACT drugs [87,88,89,90,91]. More recently, Bonnet et al. reported the synthesis and photochemistry of the Ru(II) polypyridyl complex [Ru(bpy)2(3H)]2+ (43) [92], where 3H is a photolabile bis(thioether) ligand. Complex 43 was bound to the surface of Lanthanoid-doped UCNPs through its bis(phosphonate) group, thereby creating an H2O-dispersible, thermally stable nanoconjugate. The incorporation of the neodymium-doped shell allowed for activation of 43 by 796 nm irradiation, which prevents the undesired heating seen with conventional UCNPs activated at 980 nm.
Additionally, two-photon absorption has been utilized for photoactivation of Ru(II) complexes, in which the prodrugs are activated by radiation in the PDT window [93,94,95,96]. Recently, by simply using a pyrene-modified-terpyridine (tpy-Py) as the labile bidentate ligand, Zhou et al. designed and synthesized a promising Ru(II) polypyridine complex 44, which shows dual PACT and PDT activity upon efficient two-photon excitation in the NIR region [97]. Complex 44 can potently inactivate hypoxic and cisplatin-resistant cancer cells upon two-photon excitation at 800 nm.

4. Ru(II) PACT Agents with Multiple Functions

As previously described, photoinduced ligand dissociation of the Ru(II) polypyridine complex was achieved by the thermal population of 3MC states from the lower-lying 3MLCT states. Therefore, the rational and precise regulation of the energy levels of MLCT, MC, and LC states can theoretically regulate the ratio of each decay pathway, which may endue the complexes with multiple functions.

4.1. Ru(II) Complexes with Dual PACT and PDT Activity

Based on the classical photoinduced ligand dissociation of complex 3, Dunbar’s and Turro’s groups further introduced a dppn (benzo[i]dipyrido-[3,2-a;2′,3′-c]phenazine) ligand with low 3ππ* energy level [98]. The complex [Ru (bpy)(dppn)(CH3CN)2]2+ (45, Figure 7) can not only dissociate the CH3CN ligands through 3MC state to form hydrate [Ru(bpy)(dppn)(H2O)2]2+ under 460 nm illumination (Φ < 1%), but can also produce 1O2 (Φ = 0.72, in methanol) thanks to the long-lived 3ππ* (dppn) state, realizing the combination of PACT and PDT in one Ru(II) complex. Although the ligand photodissociation efficiency of 45 was relatively low, complex 45 was highly cytotoxic towards HL60 cancer cells under 466 nm irradiation, with a PI value of 1110, which is much higher than that of the model complexes [Ru(bpy)2(dppn)]2+ (PI = 282) and 3 (PI = 6.4). By utilizing the steric bulk, Turro’s group further expanded the study of these Ru(II) complexes with dual photoreactivity [99,100,101,102], such as complex [Ru(tpy)(Me2dppn)py]2+ (46, tpy = terpiridine).
Recently, a series of Ru(II) complexes 47–49 containing arylated derivatives of the ligand Me2dppn were reported [103]. Complexes 47–49 displayed greater lipophilicity relative to 46, and can interact with DNA in an electrostatic manner instead of intercalation. Quantum yields for photodissociation of the monodentate pyridines in 47–49 were about three times higher than that of 46, whereas quantum yields for 1O2 generation were about 10% lower. Complexes 47–49 showed photoactivated toxicity in breast and prostate cancer cell lines, and PIs were lower than that of 46.
The complexes 50 and 51 were designed and synthesized by using pyridine sulfonic acid (py-SO3) as the leaving group [104,105]. It was found that 50 and 51 can undergo py-SO3 dissociation upon visible light irradiation and produce reactive free radical species, and is therefore able to photobind and photocleave DNA simultaneously in hypoxic conditions. Unexpectedly, poor cell phototoxicity was observed for these two complexes. Lately, another py-SO3- based complex 52 was synthesized and studied by the same research group [106], which displayed efficient phototoxicity towards a series of cancer cells, including cisplatin-resistant human ovarian adenocarcinoma cells (SKOV3) and human lung adenocarcinoma cells (A549). Detailed studies indicated that the high cytotoxicity of 52 may be attributed to its enhanced cell uptake and nuclear accumulation levels. Patra et al. designed and synthesized two Ru complexes of saccharin with dipyridoquinoxaline and dipyridophenazine. Upon irradiation with UV-A light of 365 nm, both complexes can undergo photoinduced dissociation of saccharin ligand and generate reactive oxygen species, showing dual PDT and PACT activities [107].

4.2. The Combination of Ru(II)-Based PACT and Bioactive Ligands

By replacing the photolabile ligands in Ru-based PACT drugs with bioactive molecules, such as small molecule drugs and enzyme inhibitors, the resulting Ru(II) complexes may possess dual activity. Upon light activation, these complexes can release active ligands that may directly kill cancer cells, while the Ru(II) aqua species are able to damage DNA simultaneously.
Dunbar’s and Turro’s groups designed and synthesized 53 and 54 (Figure 8) using 5-cyano uracil (5CNU), a derivative of the chemotherapeutic drug 5-fluorouracil (5FU), as the leaving ligand [108,109]. The results of the cytotoxicity experiment showed that 54 showed similar cytotoxicity to the free 5CNU ligand at the same concentration under 400 nm illumination. Bonnet et al. reported a water-soluble Ru(II) complexes 55, which can photorelease a cytotoxic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in an oxygen-independent manner [110]. A 3–4-fold increase in cytotoxicity was found upon red-light irradiation for 55, whether the cells were cultured with 1% or 21% O2.
Until now, the anticancer agent CHS-828 [111], the imidazole-based cytotoxic drug econazole [112], the anti-tuberculosis drug isoniazid [113], the inhibitor of cathepsin K [114], cytochromes P450 [115] and CYP17A1 [116], etc. successfully photoreleased from Ru-based PACT agents were reported.
Due to the dual PACT and PDT activity presented by 46, [Ru(tpy)(Me2dppn)] fragment was used to cage bioactive molecules for the purpose of achieving triple functions. Epoxysuccinyl-based inhibitors of cathepsin B (CTSB), a cysteine protease strongly associated with invasive and metastatic behavior, was conjugated to [Ru(tpy)(Me2dppn)] fragment by Kodanko et al. The study confirmed that the conjugate was capable of releasing ligand to form Ru(II) active center, generating 1O2 under light conditions, and irreversibly inhibiting CTSB, eventually causing efficient cell death [102].

4.3. Dual-Activatable Ru(II) PACT Agents

Although the photoactivation process has been effective in increasing drug selectivity, unnecessary light irradiation, such as sunlight, may still activate the prodrugs in normal tissues (such as skin), resulting in side effects. The introduction of other tumor-microenvironment-related activation factors, such as high-level GSH (glutathione), low pH values, etc., may improve the selectivity of Ru(II) PACT agents further.
Wang et al. designed and synthesized a potential GSH—responsive Ru(II) PACT agent [Ru(bpy)2(py-N = N-py)2]2+ (py-N = N-py = 4,4′-azopyridine, 56, Figure 9) by tethering a redox-active azo group on the leaving ligand [117]. The azo group can effectively quench the 3MLCT state and prevent the population of the 3MC state, which makes the target complex very stable under illumination. The DNA covalent binding capability of 56 can only be activated after GSH reduction and visible light irradiation. The concentration of GSH in tumor tissue is usually several times higher than that in normal tissue, which is also considered as a potential target of tumor tissue. This kind of GSH responsive PACT agent is expected to have a higher selectivity for tumor cells.
Considering the inherent acidity surrounding cancer cells, Papish and co-workers reported a series of pH-activated PACT agents, which can be activated by light- and pH-triggered ligand dissociation [118,119,120]. At a low pH value (pH = 5), complexes 57–61 existed in their acidic form, and the quantum yields for photodissociation were higher than in deprotonated form. Further studies validated that these complexes can produce 1O2 under illumination. Thus, they investigated how synthetic changes to ligands and ligand protonation states can influence the quantum yields for 1O2 and photodissociation. Cytotoxicity studies showed that 1O2 formation is a more plausible cause of photocytotoxicity [120].
Recently, a CO/light dual-activatable Ru(II)-oligo-(thiophene ethynylene) (Ru-OTE) agent for lysosome-targeted multimodal cancer therapeutics was reported [121]. Upon the dual-triggering of CO and light, Ru-OTE can undergo ligand substitution and generate 1O2. Importantly, Ru-OTE can be directly photoactivated using a two-photon laser (800 nm) and inhibit tumor growth in a breast tumor model.

5. Ruthenium(II) Arene Complexes

The above-mentioned Ru-based PACT agents are all Ru(II) polypyridyl complexes; in fact, another large family of Ru(II) complexes, i.e., Ru(II) arene complexes, show attractive prospects in chemotherapy [122,123]. They have the general formula [(η6-arene)Ru(L)(X)]n+ (where L is a bidentate ligand and X is a leaving ligand (usually halogen), and exhibit a spatial “piano stool” structure. The antitumor activity of these complexes is usually attributed to the formation of hydrates following the dissociation of the X ligand. When X is a halogen, the dissociation of the X ligand is spontaneous and uncontrollable. By replacing the X ligand with another monodentate ligand, such as pyridine and its derivatives, and optimizing the bidentate ligand and aromatic ring, Ru(II)-arene-based PACT agents can also be obtained.
Sadler’s group reported a series of ruthenium arene binuclear complexes (62, Figure 10) in 2007 [124]. The binuclear complexes with indene or benzene as aromatic ligands can dissociate aromatic ligands under UVA light, and the resultant hydrate can form cross-linking with DNA.
Sadler’s group [125] further designed and synthesized [(p-cym)Ru(bpm)(py)]2+ (63) by introducing an electron-deficient bidentate ligand bpm (2,2′-bipyrimidine). When excited with visible light (400–600 nm), 63 can selectively dissociate the monodentate pyridine ligand and form a reactive aqua derivative able to bind to a DNA base. After that, they investigated the structure–photoactivity relationship of this kind of complex [126]. It seems the presence of a stronger electron-donating arene can promote the formation of the aqua adduct. In order to increase the tumor-targeting, a tumor-targeting factor was introduced into 63 to form 64 [127]. Upon irradiation with visible light, the monodentate ligand was dissociated, and the hydrate generated can covalently bind to guanine in the DNA sequence. Surprisingly, in the presence of oligomeric DNA, 64 can undergo photodissociation of aromatic ligands, and the resulting polyhydrate can covalently bind with two guanines at the same time.
Wang et al. designed [(p-cym)Ru(bpy)(py-BODIPY)]2+ (65) by modifying the BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene dye) group on the py ligand [128]. The introduction of the BODIPY group effectively extends the absorption wavelength of the complex to >500 nm. Interestingly, upon selective irradiation of the absorption band of the py-BODIPY ligand, the monodentate ligand can dissociate rapidly, and the resultant hydrate can covalently bind with the DNA base. It was found that photoinduced electron transfer from the BODIPY to the Ru(II) arene moiety plays an important role in the ligand dissociation. Based on the above results, they further synthesized [(p-cym)Ru (bpy)(py-Fc)]2+ (66) by introducing the ferrocene (Fc) group with redox activity on the py ligand [129]. The introduction of the ferrocene group makes 66 have a long-wavelength absorption band extending to 600 nm. Moreover, 66 can generate both hydroxyl radicals (·OH) and 1O2 along with photoinduced monodentate ligand dissociation, leading to phototoxicity against SKOV3 and A549.
An intriguing mononuclear Ru(II) arene complex [(p-cym)Ru(dpb)(py)]2+ (67) [130] with a dpb (2,3-bis(2-pyridyl)-benzoquinoxaline) ligand was synthesized and scrutinized by the same research group. The bulky features of the dpb ligand result in a strained coordination sphere of 67, which leads to the photodissociation of both monodentate and bidentate ligands. The highly delocalized nature of dpb provides 67 with long-wavelength-absorbing properties and the ability to generate 1O2. The cytotoxicity test showed that the complex could effectively kill A549 cells under light conditions with a PI value of 6.9. Subsequently, a series of [(p-cym)Ru(dpb)(py-R)]2+complexes (68–72) were synthesized and compared to disclose the substituent effect on the py ligand [131]. It seems that the electron-withdrawing groups facilitate both 1O2 generation and ligand photodissociation.
García et al. investigated a neutral Ru(II) arene complex 73 bearing a benzothiazole ligand (HL2) as the bidentate ligand [132]. The results of this study indicated that the arene ligand is released after irradiation with UV light even in the absence of oxygen and leads to cytotoxicity enhancement, thus revealing the potential of 73 as a prodrug for PACT.

6. Conclusions and Future Perspectives

The research on Ru(II)-based PACT agents has been a hotspot in the field of metal anticancer drugs in recent years. Thanks to the efforts of many groups, continuous progress has been achieved in recent years. However, there is still a long way to realize the clinical applications of these Ru(II)-based PACT agents.
First, the photoactivation wavelength needs to be further extended. However, prolonging the MLCT absorption wavelength will increase the energy gap between the 3MLCT state and the 3MC state, which will, unfortunately, reduce the ligand dissociation efficiency. How to prolong the activation wavelength without sacrificing the ligand dissociation efficiency is full of challenges.
Second, most of the current studies focus on the ligand photodissociation-related photophysical and photochemical properties, while less attention is paid to the structure–activity relationship of antitumor activity. Many Ru(II) complexes displayed efficient photoinduced ligand dissociation; however, little anticancer activity was observed. Therefore, in addition to the ligand photodissociation, more efforts are needed to disclose how the other factors (such as DNA binding, cellular uptake, subcellular localization, etc.) influence the anticancer activity of Ru(II) PACT agents.
Third, the real cellular anticancer targets of Ru(II) PACT agents are still unknown. DNA is proposed as the potential target, and indeed many studies have verified that Ru(II) complexes with photolabile ligands can form Ru–DNA covalent binding in solutions after photoinduced ligand dissociation. However, some of the reported Ru(II) complexes with efficient PACT activity cannot attend the nucleus, which may hint to us that DNA should not be the only target. To disclose the real anticancer mechanism can undoubtedly promote the rational design of efficient Ru(II) PACT agents.
Fourth, among the existing reports on Ru(II)-based PACT agents, only a few studies were conducted at the living animal level. Although some promising results in vitro have been achieved so far, the lack of research in vivo is not conducive to promoting the clinical application of these complexes. Obviously, Ru(II) PACT agents may not be suitable to treat all kinds of cancers; thus, finding the possible indications of Ru(II) PACT is meaningful.
The research of Ru(II)-based PACT agents may still be at the early stage. We hope the current review can inspire more researchers with different backgrounds to enter this interesting field.

Author Contributions

Conceptualization, Y.C. and Q.Z.; investigation, L.B., P.Z., and H.Z.; writing—original draft preparation, Y.C.; writing—review and editing, Y.C. and Q.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (21701018, 21571181, 21773277), the Science and Technology Planning Project of Yuzhong District of Chongqing City (Grant No. 20200125), and the discipline talent training program of the College of Pharmacy (YXY2020SDTR01).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We also thank the College of Pharmacy, Chongqing Medical University, for partial financial support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Romero-Canelón, I.; Sadler, P.J. Next-generation metal anticancer complexes: Multitargeting via redox modulation. Inorg. Chem. 2013, 52, 12276–12291. [Google Scholar] [CrossRef]
  2. Mjos, K.D.; Orvig, C. Metallodrugs in Medicinal Inorganic Chemistry. Chem. Rev. 2014, 114, 4540–4563. [Google Scholar] [CrossRef]
  3. Das, U.; Kar, B.; Pete, S.; Paira, P. Ru(II), Ir(III), Re(I) and Rh(III) based complexes as next generation anticancer metallopharmaceuticals. Dalton Trans. 2021, 50, 11259–11290. [Google Scholar] [CrossRef]
  4. Ma, D.L.; He, H.Z.; Leung, K.H.; Chan, D.S.; Leung, C.H. Bioactive luminescent transition-metal complexes for biomedical applications. Angew. Chem. Int. Ed. 2013, 52, 7666–7682. [Google Scholar] [CrossRef] [PubMed]
  5. Ohata, J.; Ball, Z.T. Rhodium at the chemistry-biology interface. Dalton Trans. 2018, 47, 14855–14860. [Google Scholar] [CrossRef]
  6. Ma, D.L.; Wu, C.; Wu, K.J.; Leung, C.H. Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells. Molecules 2019, 24, 2739. [Google Scholar] [CrossRef] [Green Version]
  7. Omondi, R.O.; Ojwach, S.O.; Jaganyi, D. Review of comparative studies of cytotoxic activities of Pt(II), Pd(II), Ru(II)/(III) and Au(III) complexes, their kinetics of ligand substitution reactions and DNA/BSA interactions. Inorg. Chim. Acta. 2020, 512, 119883. [Google Scholar] [CrossRef]
  8. Rosenberg, B.; Vancamp, L.; Krigas, T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature 1965, 205, 698–699. [Google Scholar] [CrossRef] [PubMed]
  9. Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum Compounds: A new class of potent antitumor agents. Nature 1969, 222, 385–386. [Google Scholar] [CrossRef] [PubMed]
  10. Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113–8127. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Galanski, M.; Jakupec, M.A.; Keppler, B.K. Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Curr. Med. Chem. 2005, 12, 2075–2098. [Google Scholar] [CrossRef] [PubMed]
  12. Zheng, Y.R.; Suntharalingam, K.; Johnstone, T.C.; Yoo, H.; Lin, W.; Brooks, J.G.; Lippard, S.J. Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery. J. Am. Chem. Soc. 2014, 136, 8790–8798. [Google Scholar] [CrossRef] [Green Version]
  13. Graf, N.; Bielenberg, D.R.; Kolishetti, N.; Muus, C.; Banyard, J.; Farokhzad, O.C.; Lippard, S.J. αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug. ACS Nano. 2012, 6, 4530–4539. [Google Scholar] [CrossRef] [Green Version]
  14. Suntharalingam, K.; Song, Y.; Lippard, S.J. Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy. Chem. Commun. 2014, 50, 2465–2468. [Google Scholar] [CrossRef] [Green Version]
  15. Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016, 116, 3436–3486. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Fanelli, M.; Formica, M.; Fusi, V.; Giorgi, L.; Micheloni, M.; Paoli, P. New trends in platinum and palladium complexes as antineoplastic agents. Coord. Chem. Rev. 2016, 310, 41–79. [Google Scholar] [CrossRef]
  17. Farrer, N.J.; Woods, J.A.; Salassa, L.; Zhao, Y.; Robinson, K.S.; Clarkson, G.; Mackay, F.S.; Sadler, P.J. A Potent Trans-Diimine Platinum Anticancer Complex Photoactivated by Visible Light. Angew. Chem. Int. Ed. 2010, 49, 8905–8908. [Google Scholar] [CrossRef]
  18. Kasparkova, J.; Kostrhunova, H.; Novakova, O.; Křikavová, R.; Va nčo, J.; Trávníčk, Z.; Brabec, V. A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases. Angew. Chem. Int. Ed. 2015, 54, 14478–14482. [Google Scholar] [CrossRef]
  19. Farrer, N.J.; Salassa, L.; Sadler, P.J. Photoactivated chemotherapy (PACT): The potential of excited-state d-block metals in medicine. Dalton Trans. 2009, 10690–10701. [Google Scholar] [CrossRef]
  20. Imberti, C.; Zhang, P.; Huang, H.; Sadler, P.J. New Designs for Phototherapeutic Transition Metal Complexes. Angew. Chem. Int. Ed. 2020, 59, 61–73. [Google Scholar] [CrossRef] [PubMed]
  21. Bonnet, S. Why develop photoactivated chemotherapy? Dalton Trans. 2018, 47, 10330–10343. [Google Scholar] [CrossRef]
  22. Detty, M.R.; Gibson, S.L.; Wagner, S.J. Current Clinical and Preclinical Photosensitizers for Use in Photodynamic Therapy. J. Med. Chem. 2004, 47, 3897–3915. [Google Scholar] [CrossRef]
  23. Fan, W.; Huang, P.; Chen, X. Overcoming the Achilles’ heel of photodynamic therapy. Chem. Soc. Rev. 2016, 45, 6488–6519. [Google Scholar] [CrossRef]
  24. Eales, K.L.; Hollinshead, K.E.R.; Tennant, D.A. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 2016, 5, e190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Cosse, J.P.; Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem. 2008, 8, 790–797. [Google Scholar] [CrossRef]
  26. Alagesan, M.; Sathyadevi, P.; Krishnamoorthy, P.; Bhuvanesh, N.S.; Dharmaraj, N. DMSO containing ruthenium(II) hydrazone complexes: In vitro evaluation of biomolecular interaction and anticancer activity. Dalton Trans. 2014, 43, 15829–15840. [Google Scholar] [CrossRef] [PubMed]
  27. Thota, S.; Rodrigues, D.A.; Crans, D.C.; Barreiro, E.J. Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics? J. Med. Chem. 2018, 61, 5805–5821. [Google Scholar] [CrossRef]
  28. Notaro, A.; Gasser, G. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(II) polypyridyl complexes as anticancer drug candidates. Chem. Soc. Rev. 2017, 46, 7317–7337. [Google Scholar] [CrossRef] [PubMed]
  29. Sun, Q.; Li, Y.; Shi, H.; Wang, Y.; Zhang, J.; Zhang, Q. Ruthenium Complexes as Promising Candidates against Lung Cancer. Molecules 2021, 26, 4389. [Google Scholar] [CrossRef]
  30. Poynton, F.E.; Bright, S.A.; Blasco, S.; Williams, D.C.; Kelly, J.M.; Gunnlaugsson, T. The development of ruthenium(II) polypyridylcomplexes and conjugates for in vitro cellular and in vivo applications. Chem. Soc. Rev. 2017, 46, 7706–7756. [Google Scholar] [CrossRef]
  31. Bergamo, A.; Zorzet, S.; Gava, B.; Sorc, A.; Alessio, E.; Iengo, E.; Sava, G. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. Anti-Cancer Drugs. 2000, 11, 665–672. [Google Scholar] [CrossRef] [PubMed]
  32. Bratsos, I.; Jedner, S.; Gianferrara, T.; Alessio, E. Ruthenium Anticancer Compounds: Challenges and Expectations. CHIMIA 2007, 61, 692–697. [Google Scholar] [CrossRef]
  33. Rademaker-Lakhai, J.M.; van den Bongard, D.; Pluim, D.; Beijnen, J.H.; Schellens, J.H. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent. Clin. Cancer Res. 2004, 10, 3717–3727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Hartinger, C.G.; Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside—preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 2006, 100, 891–904. [Google Scholar] [CrossRef] [PubMed]
  35. Bytzek, A.K.; Koellensperger, G.; Keppler, B.K.; Hartinger, C.G. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. J. Inorg. Biochem. 2016, 160, 250–255. [Google Scholar] [CrossRef]
  36. Leijen, S.; Burgers, S.A.; Baas, P.; Pluim, D.; Tibben, M.; Werkhoven, E.; Alessio, E.; Sava, G.; Beijnen, J.H.; Schellens, J.H.M. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investig. New Drugs. 2015, 33, 201–214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Monro, S.; Colón, K.L.; Yin, H.; Roque, J.; Konda, P.; Gujar, S.; Thummel, R.P.; Lilge, L.; Gameron, C.G.; McFarland, S.A. Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433. Chem. Rev. 2019, 119, 797–828. [Google Scholar] [CrossRef]
  38. Mari, C.; Pierroz, V.; Ferrari, S.; Gasser, G. Combination of Ru(II) complexes and light: New frontiers in cancer therapy. Chem. Sci. 2015, 6, 2660–2686. [Google Scholar] [CrossRef] [Green Version]
  39. Knoll, J.D.; Turro, C. Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy. Coord. Chem. Rev. 2015, 282, 110–126. [Google Scholar] [CrossRef] [Green Version]
  40. Zeng, L.; Gupta, P.; Chen, Y.; Wang, E.; Ji, L.; Chao, H.; Chen, Z.S. The development of anticancer ruthenium(II) complexes: From single molecule compounds to nanomaterials. Chem. Soc. Rev. 2017, 46, 5771–5804. [Google Scholar] [CrossRef]
  41. Li, A.; Turro, C.; Kodanko, J.J. Ru(II) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles. Chem. Commun. 2018, 54, 1280–1290. [Google Scholar] [CrossRef] [PubMed]
  42. Zhang, C.X.; Lippard, S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 2003, 7, 481–489. [Google Scholar] [CrossRef]
  43. Grover, N.; Welch, T.W.; Fairley, T.A.; Cory, M.; Thorp, H.H. Covalent Binding of Aquaruthenium complexes to DNA. Inorg. Chem. 1994, 33, 3544–3548. [Google Scholar] [CrossRef]
  44. Gill, M.R.; Thomas, J.A. Ruthenium (II) polypyridyl complexes and DNA-from structural probes to cellular imaging and therapeutics. Chem. Soc. Rev. 2012, 41, 3179–3192. [Google Scholar] [CrossRef] [PubMed]
  45. Albani, B.A.; Peña, B.; Dunbar, K.R.; Turro, C. New cyclometallated Ru(II) complex for potential application in photochemotherapy. Photochem. Photobiol. Sci. 2014, 13, 272–280. [Google Scholar] [CrossRef] [PubMed]
  46. Durham, B.; Walsh, J.L.; Carter, C.L.; Meyer, T.J. Synthetic applications of photosubstitution reactions of poly(pyridyl) complexes of ruthenium(II). Inorg. Chem. 1980, 19, 860–865. [Google Scholar] [CrossRef]
  47. Hu, X.; Liu, N.Y.; Deng, Y.Q.; Wang, S.; Liu, T.; Liu, X.W. Photoinduced DNA Cleavage and Photocytotoxic of Phenanthroline-Based Ligand Ruthenium Compounds. Molecules 2021, 26, 3471. [Google Scholar] [CrossRef]
  48. Zhou, Q.X.; Lei, W.H.; Sun, Y.; Chen, J.R.; Li, C.; Hou, Y.J.; Wang, X.S.; Zhang, B.W. [Ru(bpy)3-n(dpb)n]2+: Unusual Photophysical Property and Efficient DNA Photocleavage Activity. Inorg. Chem. 2010, 49, 4729–4731. [Google Scholar] [CrossRef]
  49. Jakubaszek, M.; Goud, B.; Ferrari, S.; Gasser, G. Mechanisms of action of Ru(II) polypyridyl complexes in living cells upon light irradiation. Chem. Commun. 2018, 54, 13040–13059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Singh, T.N.; Turro, C. Photoinitiated DNA Binding by cis-[Ru(bpy)2(NH3)2]2+. Inorg. Chem. 2004, 43, 7260–7362. [Google Scholar] [CrossRef]
  51. Rillema, D.P.; Blanton, C.B.; Shaver, R.J.; Jackman, D.C.; Bolda-ji, M.; Bundy, S.; Worl, L.A.; Meyer, T.J. MLCT-dd Energy Gap in Pyridyl-Pyrimidine and Bis( pyridine) Complexes of Ruthenium(II). Inorg. Chem. 1992, 31, 1600–1606. [Google Scholar] [CrossRef]
  52. Liu, Y.; Turner, D.B.; Singh, T.N.; Angeles-Boza, A.M.; Chouai, A.; Dunbar, K.R.; Turro, C. Ultrafast ligand exchange: Detection of a pentacoordinate Ru(II) intermediate and product formation. J. Am. Chem. Soc. 2009, 131, 26–27. [Google Scholar] [CrossRef]
  53. Kayanuma, M.; Shoji, M.; Shigeta, Y. Photosubstitution Reaction of cis-[Ru(bpy)2(CH3CN)2]2+ and cis-[Ru(bpy)2(NH3)2]2+ in Aqueous Solution via Monoaqua Intermediate. J. Phys. Chem. A 2019, 123, 2497–2502. [Google Scholar] [CrossRef]
  54. Havrylyuk, D.; Deshpande, M.; Parkin, S.; Glazer, E.C. Ru(II) complexes with diazine ligands: Electronic modulation of the coordinating group is key to the design of “dual action” photoactivated agents. Chem. Commun. 2018, 54, 12487–12490. [Google Scholar] [CrossRef]
  55. Arora, K.; White, J.K.; Sharma, R.; Mazumder, S.; Martin, P.D.; Schlegel, H.B.; Turro, C.; Kodanko, J.K. Effects of Methyl Substitution in Ruthenium Tris(2-pyridylmethyl)amine Photocaging Groups for Nitriles. Inorg. Chem. 2016, 55, 6968–6979. [Google Scholar] [CrossRef] [Green Version]
  56. Li, A.; Turro, C.; Kodanko, J.J. Ru(II) Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective Photocaging. Acc. Chem Res. 2018, 51, 1415–1421. [Google Scholar] [CrossRef]
  57. Knoll, J.D.; Albani, B.A.; Durr, C.B.; Turro, C. Unusually Efficient Pyridine Photodissociation from Ru(II) Complexes with Sterically Bulky Bidentate Ancillary Ligands. J. Phys. Chem. A 2014, 118, 10603–10610. [Google Scholar] [CrossRef] [Green Version]
  58. Albani, B.A.; Durr, C.B.; Turro, C. Selective photoinduced ligand exchange in a new tris-heteroleptic Ru(II) complex. J. Phys. Chem. A 2013, 117, 13885–13892. [Google Scholar] [CrossRef]
  59. Havrylyuk, D.; Stevens, K.; Parkin, S.; Glazer, E.C. Toward Optimal Ru(II) Photocages: Balancing Photochemistry, Stability, and Biocompatibility Through Fine Tuning of Steric, Electronic, and Physiochemical Features. Inorg. Chem. 2020, 59, 1006–1013. [Google Scholar] [CrossRef]
  60. Boerhan, R.; Sun, W.; Tian, N.; Wang, Y.; Lu, J.; Li, C.; Cheng, X.; Wang, X.; Zhou, Q. Fluorination on non-photolabile dppz ligands for improving Ru(II) complex-based photoactivated chemotherapy. Dalton Trans. 2019, 48, 12177–12185. [Google Scholar] [CrossRef]
  61. Qi, S.; Jin, Z.; Jian, Y.; Hou, Y.; Li, C.; Zhao, Y.; Wang, X.; Zhou, Q. Photo-induced mitochondrial DNA damage and NADH depletion by -NO2 modified Ru(II) complexes. Chem. Commun. 2021, 57, 4162–4165. [Google Scholar] [CrossRef]
  62. Garner, R.N.; Joyce, L.E.; Turro, C. Effect of electronic structure on the photoinduced ligand exchange of Ru(II) polypyridine complexes. Inorg. Chem. 2011, 50, 4384–4391. [Google Scholar] [CrossRef] [PubMed]
  63. Howerton, B.S.; Heidary, D.K.; Glazer, E.C. Strained ruthenium complexes are potent light-activated anticancer agents. J. Am. Chem. Soc. 2012, 134, 8324–8327. [Google Scholar] [CrossRef]
  64. Hidayatullah, A.N.; Wachter, E.; Heidary, D.K.; Parkin, S.; Glazer, E.C. Photoactive Ru(II) complexes with dioxinophenanthroline ligands are potent cytotoxic agents. Inorg. Chem. 2014, 53, 10030–10032. [Google Scholar] [CrossRef]
  65. Azar, D.F.; Audi, H.; Farhat, S.; El-Sibai, M.; Abi-Habib, R.J.; Khnayzer, R.S. Phototoxicity of strained Ru(II) complexes: Is it the metal complex or the dissociating ligand? Dalton Trans. 2017, 46, 11529–11532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Wachter, E.; Heidary, D.K.; Howerton, B.S.; Parkin, S.; Glazer, E.C. Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window. Chem. Commun. 2012, 48, 9649–9651. [Google Scholar] [CrossRef] [PubMed]
  67. Dickerson, M.; Howerton, B.; Baeb, Y.; Glazer, E.C. Light-sensitive ruthenium complex-loaded cross-linked polymeric nanoassemblies for the treatment of cancer. J. Mater. Chem. B. 2016, 4, 394–408. [Google Scholar] [CrossRef] [Green Version]
  68. Bataglioli, J.C.; Gomes, L.M.F.; Maunoir, C.; Smith, J.R.; Cole, H.D.; McCain, J.; Sainuddin, T.; Cameron, C.G.; McFarland, S.A.; Storr, T. Modification of amyloid-beta peptide aggregation via photoactivation of strained Ru(II) polypyridyl complexes. Chem. Sci. 2021, 12, 7510–7520. [Google Scholar] [CrossRef]
  69. Cuello-Garibo, J.; Meijer, M.S.; Bonnet, S. To cage or to be caged? The cytotoxic species in ruthenium-based photoactivated chemotherapy is not always the metal. Chem. Commun. 2017, 53, 6768–6771. [Google Scholar] [CrossRef] [Green Version]
  70. Cuello-Garibo, J.A.; James, C.C.; Siegler, M.A.; Bonnet, S. Ruthenium-based PACT compounds based on an N,S non-toxic ligand: A delicate balance between photoactivation and thermal stability. Chem. Sq. 2017, 1, 2. [Google Scholar] [CrossRef] [Green Version]
  71. Friedman, A.E.; Chambron, J.C.; Sauvage, J.P.; Turro, N.J.; Bar-ton, J.K. A molecular light switch for DNA: Ru(bpy)2(dppz)2+. J. Am. Chem. Soc. 1990, 112, 4960–4962. [Google Scholar] [CrossRef]
  72. Wachter, E.; Howerton, B.S.; Hall, E.C.; Parkin, S.; Glazer, E.C. A new type of DNA “light-switch”: A dual photochemical sensor and metalating agent for duplex and G-quadruplex DNA. Chem. Commun. 2014, 50, 311–313. [Google Scholar] [CrossRef]
  73. Wachter, E.; Glazer, E.C. Mechanistic study on the photochemical “light switch” behavior of [Ru(bpy)2dmdppz]2+. J. Phys. Chem. A 2014, 118, 10474–10486. [Google Scholar] [CrossRef]
  74. Havrylyuk, D.; Heidary, D.K.; Sun, Y.; Parkin, S.; Glazer, E.C. Photochemical and Photobiological Properties of Pyridyl-pyrazol(in)e-Based Ruthenium(II) Complexes with Sub-micromolar Cytotoxicity for Phototherapy. ACS Omega 2020, 5, 18894–18906. [Google Scholar] [CrossRef]
  75. Dąbrowski, J.M.; Arnaut, L.G. Photodynamic therapy (PDT) of cancer: From local to systemic treatment. Photochem. Photobiol. Sci. 2015, 14, 1765–1780. [Google Scholar] [CrossRef] [PubMed]
  76. Hopkins, S.L.; Siewert, B.; Askes, S.H.C.; Veldhuizen, P.; Zwier, R.; Heger, M.; Bonnet, S. An In Vitro Cell Irradiation Protocol for Testing Photopharmaceuticals and the Effect of Blue, Green, and Red Light on Human Cancer Cell Lines. Photochem. Photobiol. Sci. 2016, 15, 644–653. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Vogel, A.; Venugopalan, V. Mechanisms of Pulsed Laser Ablation of Biological Tissues. Chem. Rev. 2003, 103, 577–644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Zhang, C.; Guo, X.; Da, X.; Wang, Z.; Wang, X.; Zhou, Q. A Ru-anthraquinone dyad with triple functions of PACT, photoredox catalysis and PDT upon red light Irradiation. Dalton Trans. 2021, 50, 10845–10852. [Google Scholar] [CrossRef]
  79. Sears, R.B.; Joyce, L.E.; Ojaimi, M.; Gallucci, J.C.; Thummel, R.P.; Turro, C. Photoinduced ligand exchange and DNA binding of cis-[Ru(phpy)(phen)(CH3CN)2]+ with long wavelength visible light. J. Inorg. Biochem. 2013, 121, 77–78. [Google Scholar] [CrossRef] [PubMed]
  80. Cuello-Garibo, J.A.; James, C.C.; Siegler, M.A.; Hopkins, S.L.; Bonnet, S. Selective Preparation of a Heteroleptic Cyclometallated Ruthenium Complex Capable of Undergoing Photosubstitution of a Bidentate Ligand. Chem. Eur. J. 2019, 25, 1260–1268. [Google Scholar] [CrossRef]
  81. Al-Afyouni, M.H.; Rohrabaugh, T.N.; Al-Afyouni, K.F.; Turro, C. New Ru(ii) photocages operative with near-IR light: New platform for drug delivery in the PDT window. Chem. Sci. 2018, 9, 6711–6720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Wang, J.; Lu, Y.; McCarthy, W.; Conway-Kenny, R.; Twamley, B.; Zhao, J.Z.; Drapera, S.M. Novel ruthenium and iridium complexes of N-substituted carbazole as triplet photosensitisers. Chem. Commun. 2018, 54, 1073–1076. [Google Scholar] [CrossRef]
  83. Wadman, S.H.; Havenith, R.W.A.; Hartl, F.; Lutz, M.; Spek, A.L.; van Klink, G.P.M.; van Koten, G. Redox Chemistry and Electronic Properties of 2,3,5,6-Tetrakis(2-pyridyl)pyrazine-Bridged Diruthenium Complexes Controlled by N,C,N′-BisCyclometalated Ligands. Inorg. Chem. 2009, 48, 5685–5696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Ruminski, R.R.; Degroff, C.; Smith, S.J. Synthesis and characterization of tetracarbonylmolybdenum(0) complexes bound to the novel bridging ligand dipyrido[2,3-a:2′,3′-h]phenazine (DPOP). Inorg. Chem. 1992, 31, 3325–3328. [Google Scholar] [CrossRef]
  85. Albani, B.A.; Peña, B.; Saha, S.; White, J.K.; Schaeffer, A.M.; Dunbar, K.R.; Turro, C. A dinuclear Ru(II) complex capable of photoinduced ligand exchange at both metal centers. Chem. Commun. 2015, 51, 16522–16525. [Google Scholar] [CrossRef]
  86. Saha, S.; Peña, B.; Dunbar, K.R. Partially Solvated Dinuclear Ruthenium Compounds Bridged by Quinoxaline-Functionalized Ligands as Ru(II) Photocage Architectures for Low-Energy Light Absorption. Inorg. Chem. 2019, 58, 14568–14576. [Google Scholar] [CrossRef]
  87. Chen, Z.; Thiramanas, R.; Schwendy, M.; Xie, C.; Parekh, S.H.; Mailänder, V.; Wu, S. Upconversion Nanocarriers Encapsulated with Photoactivatable Ru Complexes for Near-Infrared Light-Regulated Enzyme Activity. Small 2017, 13, 1700997. [Google Scholar] [CrossRef]
  88. Ruggiero, E.; Habtemariam, A.; Yate, L.; Mareque-Rivas, J.C.; Salassa, L. Near Infrared Photolysis of a Ru Polypyridyl Complex by Upconverting Nanoparticles. Chem. Commun. 2014, 50, 1715–1718. [Google Scholar] [CrossRef] [PubMed]
  89. Shi, H.; Fang, T.; Tian, Y.; Huang, H.; Liu, Y. A Dual-Fluorescent Nano-Carrier for Delivering Photoactive Ruthenium Polypyridyl Complexes. J. Mater. Chem. B 2016, 4, 4746–4753. [Google Scholar] [CrossRef] [PubMed]
  90. Chen, Y.; Jiang, G.; Zhou, Q.; Zhang, Y.; Li, K.; Zheng, Y.; Zhang, B.; Wang, X. An upconversion nanoparticle/Ru(II) polypyridyl complex assembly for NIR-activated release of a DNA covalent-binding agent. RSC Adv. 2016, 6, 23804–23808. [Google Scholar] [CrossRef]
  91. Zhang, C.; Guo, X.; Da, X.; Yao, Y.; Xiao, H.; Wang, X.; Zhou, Q. UCNP@BSA@Ru nanoparticles with tumor-specific and NIR-triggered efficient PACT activity in vivo. Dalton Trans. 2021, 50, 7715–7724. [Google Scholar] [CrossRef]
  92. Meijer, M.S.; Natile, M.M.; Bonnet, S. 796 nm Activation of a Photocleavable Ruthenium(II) Complex Conjugated to an Upconverting Nanoparticle through Two Phosphonate Groups. Inorg. Chem. 2020, 59, 14807–14818. [Google Scholar] [CrossRef] [Green Version]
  93. Greenough, S.E.; Horbury, M.D.; Smith, N.A.; Sadler, P.J.; Pater-son, M.J.; Stavros, V.G. Excited-State Dynamics of a Two-Photon-Activatable Ruthenium Prodrug. ChemPhysChem 2016, 17, 221–224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Ávila, M.R.; León-Rojas, A.F.; Lacroix, P.G.; Malfant, I.; Farfán, N.; Mhanna, R.; Santillan, R.; Ramos-Ortiz, G.; Malval, J.P. Two-Photon-Triggered NO Release via a Ruthenium–Nitrosyl Complex with a Star-Shaped Architecture. Phys. Chem. Lett. 2020, 11, 6487–6491. [Google Scholar] [CrossRef]
  95. Li, H.; Xie, C.; Lan, R.; Zha, S.; Chan, C.; Wong, W.; Ho, K.; Chan, B.D.; Luo, Y.; Zhang, J.; et al. A Smart Europium−Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations. J. Med. Chem. 2017, 60, 8923–8932. [Google Scholar] [CrossRef] [PubMed]
  96. Wang, Y.; Tian, N.; Sun, W.; Rena, B.; Guo, X.; Feng, Y.; Li, C.; Wang, X.; Zhou, Q. A Ru(II)-Based Nanoassembly Exhibiting Theranostic PACT Activity in NIR Region. Part. Part. Syst. Charact. 2020, 37, 2000045. [Google Scholar] [CrossRef]
  97. Jin, Z.; Qi, S.; Guo, X.; Jian, Y.; Hou, Y.; Li, C.; Wang, X.; Zhou, Q. The modification of a pyrene group makes a Ru(II) complex versatile. Chem. Commun. 2021, 57, 3259–3262. [Google Scholar] [CrossRef] [PubMed]
  98. Albani, B.A.; Peña, B.; Leed, N.A.; de Paula, N.A.B.G.; Pavani, C.; Baptista, M.S.; Dunbar, K.R.; Turro, C. Marked improvement in photoinduced cell death by a new tris-heteroleptic complex with dual action: Singlet oxygen sensitization and ligand dissociation. J. Am. Chem. Soc. 2014, 136, 17095–17101. [Google Scholar] [CrossRef]
  99. Knoll, J.D.; Albani, B.A.; Turro, C. Excited state investigation of a new Ru(II) complex for dual reactivity with low energy light. Chem. Commun. 2015, 51, 8777–8780. [Google Scholar] [CrossRef] [Green Version]
  100. Knoll, J.D.; Albani, B.A.; Turro, C. New Ru(II) Complexes for Dual Photoreactivity: Ligand Exchange and 1O2 Generation. Acc. Chem. Res. 2015, 48, 2280–2287. [Google Scholar] [CrossRef] [Green Version]
  101. Loftus, L.M.; White, J.K.; Albani, B.A.; Kohler, L.; Kodanko, J.K.; Thummel, R.P.; Dunba, K.R.; Turro, C. New RuII Complex for Dual Activity: Photoinduced Ligand Release and 1O2 Production. Chem. Eur. J. 2016, 22, 3704–3708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Arora, K.; Herroon, M.; Al-Afyouni, M.H.; Toupin, N.P.; Rohrabaugh, T.N.; Loftus, L.M.; Podgorski, I.; Turro, C.; Kodanko, J.J. Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers. J. Am. Chem. Soc. 2018, 140, 14367–14380. [Google Scholar] [CrossRef] [PubMed]
  103. Toupin, N.P.; Nadella, S.; Steinke, S.J.; Turro, C.; Kodanko, J.J. Dual-Action Ru(II) Complexes with Bulky π-Expansive Ligands: Phototoxicity without DNA Intercalation. Inorg. Chem. 2020, 59, 3919–3933. [Google Scholar] [CrossRef] [PubMed]
  104. Zheng, Y.; Zhou, Q.X.; Lei, W.H.; Hou, Y.J.; Li, K.; Chen, Y.J.; Zhang, B.W.; Wang, X.S. DNA photocleavage in anaerobic conditions by a Ru(II) complex: A new mechanism. Chem. Commun. 2015, 51, 428–430. [Google Scholar] [CrossRef]
  105. Zheng, Y.; Zhou, Q.X.; Zhang, Y.Y.; Li, C.; Hou, Y.J.; Wang, X.S. Substituent effect and wavelength dependence of the photoinduced Ru-O homolysis in the [Ru(bpy)2(py-SO3)]+-type complexes. Dalton Trans. 2016, 45, 2897–2905. [Google Scholar] [CrossRef] [Green Version]
  106. Tian, N.; Feng, Y.; Sun, W.; Lu, J.; Lu, S.; Yao, Y.; Li, C.; Wang, X.; Zhou, Q. A nuclear permeable Ru(II)-based photoactivated chemotherapeutic agent towards a series of cancer cells: In vitro and in vivo studies. Dalton Trans. 2019, 48, 6492–6500. [Google Scholar] [CrossRef] [PubMed]
  107. Kumar, P.; Dasari, S.; Patra, A.K. Ruthenium(II) complexes of saccharin with dipyridoquinoxaline and dipyridophenazine: Structures, biological interactions and photoinduced DNA damage activity. Eur. J. Med. Chem. 2017, 136, 52–62. [Google Scholar] [CrossRef]
  108. Gamer, B.N.; Gallucci, J.C.; Dunbar, K.R.; Turro, C. [Ru(bpy)2(5-cyanouracil)2]2+ as a Potential Light-Activated Dual-Action Therapeutic Agent. Inorg. Chem. 2011, 50, 9213–9215. [Google Scholar]
  109. Sgambellone, M.A.; David, A.; Garner, R.N.; Dunbar, K.R.; Turro, C. Cellular Toxicity Induced by the Photorelease of a Caged Bioactive Molecule: Design of a Potential Dual-Action Ru(II) Complex. J. Am. Chem. Soc. 2013, 135, 11274–11282. [Google Scholar] [CrossRef]
  110. Lameijer, L.N.; Ernst, D.; Hopkins, S.L.; Meijer, M.S.; Askes, S.H.C.; Le Devedec, S.E.; Bonnet, S. A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in HypoxicCancer Cells. Angew. Chem. Int. Ed. 2017, 56, 11549–11553. [Google Scholar] [CrossRef]
  111. Wei, J.H.; Renfrew, A.K. Photolabile Ruthenium Complexes to Cage and Release a Highly Cytotoxic Anticancer Agent. J. Inorg. Biochem. 2018, 179, 146–153. [Google Scholar] [CrossRef]
  112. Karaoun, N.; Renfrew, A.K. A Luminescent Ruthenium(II) Complex for Light-Triggered Drug Release and Live Cell Imaging. Chem. Commun. 2015, 51, 14038–14041. [Google Scholar] [CrossRef]
  113. Smith, N.A.; Zhang, P.Y.; Greenough, S.E.; Horbury, M.D.; Clarkson, G.J.; McFeely, D.; Habtemariam, A.; Salassa, L.; Stavros, V.G.; Dowson, C.G.; et al. Combatting AMR: Photoactivatable Ruthenium(II)-Isoniazid Complex Exhibits Rapid Selective Antimycobacterial Activity. Chem. Sci. 2017, 8, 395–404. [Google Scholar] [CrossRef] [Green Version]
  114. Herroon, M.K.; Sharma, R.; Rajagurubandara, E.; Turro, C.; Kodanko, J.J.; Podgorski, I. Photoactivated Inhibition of Cathepsin K in a 3D Tumor Model. Biol. Chem. 2016, 397, 571–582. [Google Scholar] [CrossRef] [Green Version]
  115. Zamora, A.; Denning, C.A.; Heidary, D.K.; Wachter, E.; Nease, L.A.; Ruiz, J.; Glazer, E.C. Ruthenium-Containing p450 Inhibitors for Dual Enzyme Inhibition and DNA Damage. Dalton Trans. 2017, 46, 2165–2173. [Google Scholar] [CrossRef] [PubMed]
  116. Li, A.; Yadav, R.; White, J.K.; Herroon, M.K.; Callahan, B.P.; Podgorski, I.; Turro, C.; Scott, E.E.; Kodanko, J.J. Illuminating Cytochrome P450 Binding: Ru(II)-Caged Inhibitors of CYP17A1. Chem. Commun. 2017, 53, 3673–3676. [Google Scholar] [CrossRef] [PubMed]
  117. Zhou, Q.X.; Zheng, Y.; Wang, T.J.; Chen, Y.J.; Li, K.; Zhang, Y.Y.; Li, C.; Hou, Y.J.; Wang, X.-S. A novel azopyridine-based Ru(ii) complex with GSH-responsive DNA photobinding ability. Chem. Commun. 2015, 51, 10684–10686. [Google Scholar] [CrossRef]
  118. Qu, F.; Park, S.; Martinez, K.; Gray, J.L.; Thowfeik, F.S.; Lundeen, J.A.; Kuhn, A.E.; Charboneau, D.J.; Gerlach, D.L.; Lockart, M.M.; et al. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells. Inorg. Chem. 2017, 56, 7519–7532. [Google Scholar] [CrossRef] [PubMed]
  119. Qu, F.; Martinez, K.; Arcidiacono, A.M.; Park, S.; Zeller, M.; Schmehl, R.H.; Paul, J.J.; Kim, Y.; Papish, E.T. Sterically demanding methoxy and methyl groups in ruthenium complexes lead to enhanced quantum yields for blue light triggered photodissociation. Dalton Trans. 2018, 47, 15685–15693. [Google Scholar] [CrossRef] [PubMed]
  120. Qu, F.; Lamb, R.W.; Cameron, C.G.; Park, S.; Oladipupo, O.; Gray, J.L.; Xu, Y.; Cole, H.D.; Bonizzoni, M.; Kim, Y.; et al. Singlet Oxygen Formation vs. Photodissociation for Light Responsive Protic Ruthenium Anticancer Compounds: The Oxygenated Substituent Determines Which Pathway Dominates. Inorg. Chem. 2021, 60, 2138–2148. [Google Scholar] [CrossRef]
  121. Yang, M.; Zhao, H.; Zhang, Z.; Yuan, Q.; Feng, Q.; Duan, X.; Wang, S.; Tang, Y. CO/light dual-activatable Ru(II)-conjugated oligomer agent for lysosome-targeted multimodal cancer therapeutics. Chem. Sci. 2021, 12, 11515–11524, Advance Article. [Google Scholar] [CrossRef]
  122. Suss-Fink, G. Arene ruthenium complexes as anticancer agents. Dalton Trans. 2010, 39, 1673–1688. [Google Scholar] [CrossRef]
  123. Lee, S.Y.; Kim, C.Y.; Nam, T.G. Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives. Drug Des. Devel Ther. 2020, 14, 5375–5392. [Google Scholar] [CrossRef]
  124. Magennis, S.W.; Habtemariam, A.; Novakova, O.; Henry, J.B.; Meier, S.; Parsons, S.; Oswald, L.D.H.; Brabec, V.; Sadler, P.J. Dual Triggering of DNA Binding and Fluorescence via Photoactivation of a Dinuclear Ruthenium(II) Arene Complex. Inorg. Chem. 2007, 46, 5059–5068. [Google Scholar] [CrossRef]
  125. Betanzos-Lara, S.; Salassa, L.; Habtemariam, A.; Sadler, P.J. Photocontrolled nucleobase binding to an organometallic RuII arene complex. Chem. Commun. 2009, 43, 6622–6624. [Google Scholar] [CrossRef] [PubMed]
  126. Betanzos-Lara, S.; Salassa, L.; Habtemariam, A.; Novakova, O.; Pizarro, A.M.; Clarkson, G.J.; Liskova, B.; Brabec, V.; Sadler, P.J. Photoactivatable Organometallic Pyridyl Ruthenium(II) Arene Complexes. Organometallics 2012, 31, 3466–3479. [Google Scholar] [CrossRef]
  127. Barragán, F.; López-Senín, P.; Salassa, L.; Betanzos-Lara, S.; Habtemariam, A.; Moreno, V.; Sadler, P.J.; Marchán, V. Photocontrolled DNA Binding of a Receptor-Targeted OrganometallicRuthenium(II) Complex. J. Am. Chem. Soc. 2011, 133, 14098–14108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Zhou, Q.X.; Lei, W.H.; Hou, Y.J.; Chen, Y.J.; Li, C.; Zhang, B.W.; Wang, X.S. BODIPY-modified Ru(II) arene complex—a new ligand dissociation mechanism and a novel strategy to red shift the photoactivation wavelength of anticancer Metallodrugs. Dalton Trans. 2013, 42, 2786–2791. [Google Scholar] [CrossRef]
  129. Wang, T.J.; Zhou, Q.X.; Zhang, Y.Y.; Zheng, Y.; Wang, W.B.; Hou, Y.J.; Jiang, G.Y.; Cheng, X.X.; Wang, X.S. A ferrocenyl pyridine-based Ru(ii) arene complex capable of generating ·OH and 1O2 along with photoinduced ligand dissociation. RSC Adv. 2016, 6, 45652–45659. [Google Scholar] [CrossRef]
  130. Chen, Y.J.; Lei, W.H.; Jiang, G.Y.; Hou, Y.J.; Li, C.; Zhang, B.W.; Zhou, Q.X.; Wang, X.S. Fusion of photodynamic therapy and photoactivated chemotherapy: A novel Ru(II) arene complex with dual activities of photobinding and photocleavage toward DNA. Dalton Trans. 2014, 43, 15375–15384. [Google Scholar] [CrossRef]
  131. Chen, Y.J.; Lei, W.H.; Hou, Y.J.; Li, C.; Jiang, G.Y.; Zhang, B.W.; Zhou, Q.X.; Wang, X.S. Fine control on the photochemical and photobiological properties of Ru(II) arene complexes. Dalton Trans. 2015, 44, 7347–7354. [Google Scholar] [CrossRef] [PubMed]
  132. Lari, M.; Martínez-Alonso, M.; Busto, N.; Manzano, B.R.; Rodríguez, A.M.; Acuna, M.I.; Domínguez, F.; Albasanz, J.L.; Leal, J.M.; Espino, G.; et al. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes. Inorg. Chem. 2018, 57, 14322–14336. [Google Scholar] [CrossRef] [PubMed]
Molecules 26 05679 g001 550
Figure 1. Clinically approved Pt (II) anticancer drugs.
Figure 1. Clinically approved Pt (II) anticancer drugs.
Molecules 26 05679 g001
Molecules 26 05679 g002 550
Figure 2. Three ruthenium(III) complexes in clinical trials.
Figure 2. Three ruthenium(III) complexes in clinical trials.
Molecules 26 05679 g002
Molecules 26 05679 g003 550
Figure 3. Jablonski diagram of Ru(II) complexes with photolabile ligands.
Figure 3. Jablonski diagram of Ru(II) complexes with photolabile ligands.
Molecules 26 05679 g003
Molecules 26 05679 g004 550
Figure 4. Ru(II) polypyridyl complexes with photolabile monodentate ligands.
Figure 4. Ru(II) polypyridyl complexes with photolabile monodentate ligands.
Molecules 26 05679 g004
Molecules 26 05679 g005 550
Figure 5. Ru(II) polypyridyl complexes with photolabile bidentate ligands.
Figure 5. Ru(II) polypyridyl complexes with photolabile bidentate ligands.
Molecules 26 05679 g005
Molecules 26 05679 g006 550
Figure 6. Photoactivatable Ru(II) polypyridyl complexes upon long-wavelength light irradiation.
Figure 6. Photoactivatable Ru(II) polypyridyl complexes upon long-wavelength light irradiation.
Molecules 26 05679 g006
Molecules 26 05679 g007 550
Figure 7. Ru(II) complexes with dual PACT and PDT activity.
Figure 7. Ru(II) complexes with dual PACT and PDT activity.
Molecules 26 05679 g007
Molecules 26 05679 g008 550
Figure 8. Ru(II) PACT agents with photolabile bioactive molecules.
Figure 8. Ru(II) PACT agents with photolabile bioactive molecules.
Molecules 26 05679 g008
Molecules 26 05679 g009 550
Figure 9. Dual-activatable Ru(II) PACT agents.
Figure 9. Dual-activatable Ru(II) PACT agents.
Molecules 26 05679 g009
Molecules 26 05679 g010 550
Figure 10. Ru(II)-arene-complexes-based PACT agents.
Figure 10. Ru(II)-arene-complexes-based PACT agents.
Molecules 26 05679 g010
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Chen, Y.; Bai, L.; Zhang, P.; Zhao, H.; Zhou, Q. The Development of Ru(II)-Based Photoactivated Chemotherapy Agents. Molecules 2021, 26, 5679. https://doi.org/10.3390/molecules26185679

AMA Style

Chen Y, Bai L, Zhang P, Zhao H, Zhou Q. The Development of Ru(II)-Based Photoactivated Chemotherapy Agents. Molecules. 2021; 26(18):5679. https://doi.org/10.3390/molecules26185679

Chicago/Turabian Style

Chen, Yongjie, Lijuan Bai, Pu Zhang, Hua Zhao, and Qianxiong Zhou. 2021. "The Development of Ru(II)-Based Photoactivated Chemotherapy Agents" Molecules 26, no. 18: 5679. https://doi.org/10.3390/molecules26185679

APA Style

Chen, Y., Bai, L., Zhang, P., Zhao, H., & Zhou, Q. (2021). The Development of Ru(II)-Based Photoactivated Chemotherapy Agents. Molecules, 26(18), 5679. https://doi.org/10.3390/molecules26185679

Article Metrics

Back to TopTop